Log in
Enquire now
Aclaris Therapeutics

Aclaris Therapeutics

A company developing treatments for dermatology and immunology.

OverviewStructured DataIssuesContributors

Contents

aclaristx.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Technology
Technology
Pharmaceutical industry
Pharmaceutical industry
Biomedical engineering
Biomedical engineering
Biology
Biology
Biotechnology
Biotechnology
Internal medicine
Internal medicine
Medicine
Medicine
...
Location
St. Louis
St. Louis
0
Wayne County, Pennsylvania
Wayne County, Pennsylvania
0
Wayne, Pennsylvania
Wayne, Pennsylvania
United States
United States
Missouri
Missouri
Malvern, Pennsylvania
Malvern, Pennsylvania
Malvern, Arkansas
Malvern, Arkansas
0
B2X
B2B
B2B
0
D2C
D2C
CEO
‌
Neal Walker
0
Founder
‌
Frank Ruffo
‌
Neal Walker
‌
Christopher Powala
‌
Stuart D. Shanler
AngelList URL
angel.co/aclaris-therapeutics
Pitchbook URL
pitchbook.com/profiles.../55473-22
Legal Name
Aclaris Therapeutics, Inc.
Date Incorporated
2012
Number of Employees (Ranges)
51 – 200
Email Address
productcomplaint@aclaristx.com0
investors@aclaristx.com0
media@aclaristx.com0
recruiting@aclaristx.com0
medinfo@aclaristx.com0
Phone Number
+18332252747
Full Address
640 Lee Rd, Wayne, PA 19087, USA0
4340 Duncan Ave #400, St. Louis, MO 63110, USA0
CIK Number
1,557,7460
Place of Incorporation
Delaware
Delaware
0
Investors
Vivo Ventures
Vivo Ventures
Rock Springs Capital
Rock Springs Capital
Sofinnova Partners
Sofinnova Partners
‌
Fidelity Biosciences
IRS Number
460,571,7120
Founded Date
2012
Total Funding Amount (USD)
21,000,000
Latest Funding Round Date
October 24, 2012
Competitors
Aimmune Therapeutics
Aimmune Therapeutics
Nivalis Therapeutics
Nivalis Therapeutics
Stock Symbol
ACRS0
Exchange
Nasdaq
Nasdaq
0
Board of Directors
‌
William Humphries
0
‌
Neal Walker
0
‌
Andrew Schiff
0
‌
Maxine Gowen
0
‌
Anand Mehra
0
‌
Bryan Reasons
0
‌
Vincent Milano
0
Christopher Molineaux
Christopher Molineaux
0
...
CFO
‌
Frank Ruffo
0
Key People
‌
Frank Ruffo
‌
Stuart D. Shanler
‌
Neal Walker
‌
Christopher Powala
Latest Funding Type
Series A
Series A
Patents Assigned (Count)
11
Wellfound ID
aclaris-therapeutics
Country
United States
United States
0
Headquarters
Wayne, Pennsylvania
Wayne, Pennsylvania
0

Other attributes

Company Operating Status
Active
SIC Code
2,8340
Ticker Symbol
ACRS
Wikidata ID
Q107517966

Aclaris Therapeutics is a publicly held biopharmaceutical company headquartered in that was founded in 2012 by Christopher Powala, Frank Ruffo, Neal Walker, Stuart D. Shanler. It focuses on identifying, developing, and commercializing therapies to address unmet needs in dermatology, including medical, aesthetic, and immunology. The company explores therapies for market segments with no FDA-approved medications.

Products

Aclaris has two commercialized products in its portfolio, Eskata and Rhofade. Eskata is topical treatment for SKs (seborrheic keratoses). SKs are harmless spots that pop up as a person ages. Rhofade on the other hand, is a topical treatment for persistent facial erythema associated with rosacea in adults. Rhofade was originally developed by Allergan, which Aclaris then acquired the worldwide rights to.

The company also has several other product candidates in its pipeline at various stages of development. A-101 is a topical solution for the treatment of common warts that will be entering Phase 3 of clinical trials.

ATI-502 is a topical JAK1/JAK3 inhibitor that is being investigated (Phase 2) for alopecia areata, including patchy alopecia areata and the more severe forms of the disease, alopecia totalis and alopecia universalis. The product is also under investigation (Phase 2) for androgenetic alopecia, vitiligo, and atopic dermatitis. In July 2017, Aclaris filed an IND (investigational new drug) application for ATI-502.

ATI-501 is an oral JAK1/JAK3 inhibitor under investigation for the more severe forms of alopecia areata, alopecia totalis and alopecia universalis. An IND was filed in 2016 for this product. ATI-501 is a pro-drug that is converted to its active form, ATI-502.

Other product candidates in Phase 1 and pre-clinical stages are:

  • ATI-450MK2 pathway inhibitor - oral form is being investigated as a potential treatment for rheumatoid arthritis, psoriasis, hidradenitis suppurativa, cryopyrin-associated period syndroms, and pyoderma gangrenosum.
  • ATI-1777JAK1/JAK3 inhibitor - soft topical form is being investigated as a potential treatment for atopic dermatitis, vitiligo, and alopecia areata.
  • ITK/JAK3 inhibitor - soft topical and oral forms being investigated for potential in treating psoriasis, inflammatory dermatoses, and inflammatory bowel disease.
  • MK2 pathway inhibitor - oral forms being investigated for potential in oncology.
Funding
Series A

On October 24, 2012 Aclaris Therapeutics completed their series A funding round with $21 million in funding from Vivo Capital (lead investor), F-Prime Capital Partners (lead investor), and Sofinnova Ventures.

Series B

On October 2, 2014 Aclaris Therapeutics completed their series B funding round with $21million in funding from Vivo Capital, F-Prime Capital Partners, and Sofinnova Ventures.

Series C

On September 9, 2015 Aclaris Therapeutics completed their series C funding round with $40 million in funding from RA Capital Management (lead investor), Vivo Capital, Sofinnova Ventures, Rock Springs Capital, Mossrock Capital, F-Prime Capital Partners, Cormorant Asset Management, and Aperture Venture Partners.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Aclaris Therapeutics to Acquire Worldwide Rights to RHOFADE® from Allergan

Aclaris Therapeutics, Inc.

https://globenewswire.com/news-release/2018/10/15/1621519/0/en/Aclaris-Therapeutics-to-Acquire-Worldwide-Rights-to-RHOFADE-from-Allergan.html

Web

References

Find more companies like Aclaris Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.